Account Bag 0

PRODUCT PROFILE

GHRP-6 Acetate

Price range: £19.99 through £39.99

GHRP-6 is first-generation synthetic ghrelin/ghsr-1a agonist. Researchers examine it in relation to gh release alongside ghrelin-linked appetite and energy-intake signalling.

Why it is distinct

Its prominent appetite/ghrelin research profile distinguishes it from the more selective ipamorelin.

  • Evidence stageEarly human evidence
  • AvailabilityAvailable · 10 in stock
  • Batch recordPublished after verification
  • DispatchConfirmed at checkout
SKU: ADINA-GHR-GHRP-6 Category: Tags: , ,

PRODUCT INFORMATION

Clear first. Detailed when needed.

What this material is+

GHRP-6 is first-generation synthetic ghrelin/ghsr-1a agonist. Researchers examine it in relation to gh release alongside ghrelin-linked appetite and energy-intake signalling.

Research focus+

Researchers study its effects on short growth-hormone pulses and appetite signalling. It is especially distinct because hunger-related effects are often part of the research discussion.

How the mechanism differs+

Activates GHSR-1a in pituitary and hypothalamic pathways, linking GH secretion with orexigenic signalling.

Evidence and limitations+

Human endocrine challenge studies exist; evidence for broader marketed outcomes is not established.

Testing and batch documentation+

No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.

RESEARCH PROFILE

Understand the distinction.

Molecular role

First-generation synthetic ghrelin/GHSR-1a agonist

Research focus

Researchers study its effects on short growth-hormone pulses and appetite signalling. It is especially distinct because hunger-related effects are often part of the research discussion.

How it works

Activates GHSR-1a in pituitary and hypothalamic pathways, linking GH secretion with orexigenic signalling.

Key differentiator

Its prominent appetite/ghrelin research profile distinguishes it from the more selective ipamorelin.

Evidence context

Human endocrine challenge studies exist; evidence for broader marketed outcomes is not established.

Educational research context only. This information is not dosage, administration or personal-use guidance.